April 6, 2020
Modulim hit an internal milestone this month. In partnership with our clinical partners, we have acquired over 3000 images of feet using SFDI. This is a critical milestone as we aggregate SFDI biomarker data to understand the extent of circulatory compromise in patients across the diabetic foot care continuum. Studies have shown that microvascular disease can increase the risk of amputation, as does peripheral arterial disease. With SFDI, our R&D team continues to work with our key partners to build databases of oxygenation and perfusion biomarkers that can inform proactive management in the care management of patient in the entire diabetic foot care continuum.
Modulim delivers transformative optical solutions that help people live healthier, longer lives. Clarifi, powered by Spatial Frequency Domain Imaging (SFDI) technology, identifies compromised circulation at the point of care through non-contact rapid microvascular assessment of tissue. Clinicians and healthcare systems are empowered by SFDI images to make proactive, data-driven decisions in a multidisciplinary care setting, in order to reduce lower-limb complications caused by diabetes and peripheral arterial disease. Founded by the inventors of SFDI at the University of California Irvine, Modulim is based in Irvine, CA with a team dedicated to delivering powerful healthcare solutions that elevate and standardize health care delivery, while improving patient outcomes. Modulim is backed by Pangaea Ventures, Fresenius Medical Care Ventures, Grey Sky Venture Partners, Mitsubishi Capital, Hamamatsu Photonics, The Cove Fund at UCI Applied Innovation, and Fouse KK.
Clarifi is a registered trademark of Modulated Imaging (dba Modulim).
VP Sales and Marketing